Search Results - "Ollila, David W."

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes by CAREY, Lisa A, DEES, E. Claire, SAWYER, Lynda, GATTI, Lisa, MOORE, Dominic T, COLLICHIO, Frances, OLLILA, David W, SARTOR, Carolyn I, GRAHAM, Mark L, PEROU, Charles M

“…Purpose: Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among…”
Get full text

Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study by THOMAS, Nancy E, BUSAM, Klaus J, DWYER, Terence, VENN, Alison, KANETSKY, Peter A, GROBEN, Pamela A, HONGLIN HAO, ORLOW, Irene, REINER, Anne S, LI LUO, PAINE, Susan, OLLILA, David W, FROM, Lynn, WILCOX, Homer, BEGG, Colin B, BERWICK, Marianne, KRICKER, Anne, ARMSTRONG, Bruce K, ANTON-CULVER, Hoda, GRUBER, Stephen B, GALLAGHER, Richard P, ZANETTI, Roberto, ROSSO, Stefano

“…Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain…”
Get full text

LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma by Liu, Wenjin, Monahan, Kimberly B., Pfefferle, Adam D., Shimamura, Takeshi, Sorrentino, Jessica, Chan, Keefe T., Roadcap, David W., Ollila, David W., Thomas, Nancy E., Castrillon, Diego H., Miller, C. Ryan, Perou, Charles M., Wong, Kwok-Kin, Bear, James E., Sharpless, Norman E.

“…Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1…”
Get full text

Attaining Negative Margins in Breast-Conservation Operations: Is There a Consensus among Breast Surgeons? by Blair, Sarah L., MD, FACS, Thompson, Kari, MD, Rococco, Joseph, MD, Malcarne, Vanessa, PhD, Beitsch, Peter D., MD, FACS, Ollila, David W., MD, FACS

“…Background The purpose of this survey was to ascertain the most common surgical practices for attaining negative (tumor-free) surgical margins in patients…”
Get full text

Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience by Karachaliou, Georgia Sofia, Ayvali, Fatih, Collichio, Frances A, Lee, Carrie B, Ivanova, Anastasia, Ollila, David W, Moschos, Stergios J

“…Retrospective case studies in various cancers have shown clinical benefit from chemotherapy following PD-1 inhibitor progression. We asked whether we see a…”
Get more information

Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma by Berger, Adam C., MD, FACS, Ollila, David W., MD, FACS, Christopher, Adrienne, BA, Kairys, John C., MD, Mastrangelo, Michael J., MD, Feeney, Kendra, MD, Dabbish, Nooreen, PhD, Leiby, Benjamin, PhD, Frank, Jill A., MS, Stitzenberg, Karyn B., MD, FACS, Meyers, Michael O., MD, FACS

“…Abstract Background Patients with stage II melanoma have significant recurrence risk. Current guidelines are imprecise as to optimal follow-up. We hypothesized…”
Get full text

Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance) by Haffty, Bruce G., MD, McCall, Linda M., MS, Ballman, Karla V., PhD, McLaughlin, Sarah, MD, Jagsi, Reshma, MD, Ollila, David W., MD, Hunt, Kelly K., MD, Buchholz, Thomas A., MD, Boughey, Judy C., MD

“…Purpose American College of Surgeons Oncology Group Z1071 was a prospective trial evaluating the false negative rate of sentinel lymph node (SLN) surgery after…”
Get full text

Decision Making about Surgery for Early-Stage Breast Cancer by Lee, Clara N., MD, MPP, Chang, Yuchiao, PhD, Adimorah, Nesochi, BA, Belkora, Jeff K., PhD, Moy, Beverly, MD, MPH, Partridge, Ann H., MD, MPH, Ollila, David W., MD, Sepucha, Karen R., PhD

“…Background Practice variation in breast cancer surgery has raised concerns about the quality of treatment decisions. We sought to evaluate the quality of…”
Get full text

The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma by Karachaliou, Georgia Sofia, Alkallas, Rached, Carroll, Sarah B, Caressi, Chongshan, Zakria, Danny, Patel, Nirali M, Trembath, Dimitri G, Ezzell, Jennifer A, Pegna, Guillaume J, Googe, Paul B, Galeotti, Jonathan P, Ayvali, Fatih, Collichio, Frances A, Lee, Carrie B, Ollila, David W, Gulley, Margaret L, Johnson, Douglas B, Kim, Kevin B, Watson, Ian R, Moschos, Stergios J

“…Melanoma-intrinsic activated β-catenin pathway, the product of the catenin beta 1 (CTNNB1) gene, has been associated with low/absent tumor-infiltrating…”
Get full text

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma by Oldan, Jorge D., Giglio, Benjamin C., Smith, Eric, Zhao, Weiling, Bouchard, Deeanna M., Ivanovic, Marija, Lee, Yueh Z., Collichio, Frances A., Meyers, Michael O., Wallack, Diana E., Abernethy-Leinwand, Amber, Long, Patricia K., Trembath, Dimitri G., Googe, Paul B., Kowalski, Madeline H., Ivanova, Anastasia, Ezzell, Jennifer A., Nikolaishvili-Feinberg, Nana, Thomas, Nancy E., Wong, Terence Z., Ollila, David W., Li, Zibo, Moschos, Stergios J.

“…Clinical trials of combined IDO/PD1 blockade in metastatic melanoma (MM) failed to show additional clinical benefit compared to PD1-alone inhibition. We…”
Get full text

Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain Metastases by Trembath, Dimitri G, Davis, Eric S, Rao, Shanti, Bradler, Evan, Saada, Angelica F, Midkiff, Bentley R, Snavely, Anna C, Ewend, Matthew G, Collichio, Frances A, Lee, Carrie B, Karachaliou, Georgia-Sofia, Ayvali, Fatih, Ollila, David W, Krauze, Michal T, Kirkwood, John M, Vincent, Benjamin G, Nikolaishvilli-Feinberg, Nana, Moschos, Stergios J

“…High tumor-infiltrating lymphocytes (TILs) and hemorrhage are important prognostic factors in patients who have undergone craniotomy for melanoma brain…”
Get full text

Indications for Neoadjuvant Systemic Therapy for Breast Cancer by Gallagher, Kristalyn K., DO, Ollila, David W., MD

Get full text

Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma by THOMAS, Nancy E, EDMISTON, Sharon N, MATTINGLY, Dianne, OLLILA, David W, TSE, Chiu Kit, HUMMER, Amanda, LEE-TAYLOR, Julia, CONWAY, Kathleen, ALEXANDER, Audrey, MILLIKAN, Robert C, GROBEN, Pamela A, HONGLIN HAO, TOLBERT, Dawn, BERWICK, Marianne, BUSAM, Klaus, BEGG, Colin B

“…Malignant melanomas often contain BRAF or NRAS mutations, but the relationship of these mutations to ambient UV exposure in combination with phenotypic…”
Get full text

Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma by Baker, Justin J., M.D, Meyers, Michael O., M.D, Frank, Jill, M.S, Amos, Keith D., M.D, Stitzenberg, Karyn B., M.D, Ollila, David W., M.D

“…Abstract Background Follow-up of patients with sentinel lymph node–positive stage III melanoma uses history, physical exam, and cross-sectional imaging. The…”
Get full text

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment by Iles, Kathleen, Roberson, Mya L., Spanheimer, Philip, Gallagher, Kristalyn, Ollila, David W., Strassle, Paula D., Downs-Canner, Stephanie

“…Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this…”
Get full text

American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome by Carey, Lisa A., Metzger, Richard, Dees, E. Claire, Collichio, Frances, Sartor, Carolyn I., Ollila, David W., Klauber-DeMore, Nancy, Halle, Jan, Sawyer, Lynda, Moore, Dominic T., Graham, Mark L.

“…Background: Response to neoadjuvant chemotherapy is used as an intermediate endpoint for breast cancer relapse and survival. Most breast cancer response…”
Get full text

Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative) by Ollila, David W., MD, FACS, Cirrincione, Constance T., MS, Berry, Donald A., PhD, Carey, Lisa A., MD, Sikov, William M., MD, Hudis, Clifford A., MD, Winer, Eric P., MD, Golshan, Mehra, MD, FACS

“…Objectives Management of the axilla in stage II/III breast cancer undergoing neoadjuvant systemic therapy (NST) is controversial. To understand current…”
Get full text

Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer by An, Selena J., Duchesneau, Emilie D., Strassle, Paula D., Reeder-Hayes, Katherine, Gallagher, Kristalyn K., Ollila, David W., Downs-Canner, Stephanie M., Spanheimer, Philip M.

“…Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The role of de-escalated…”
Get full text

Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study by Davari, Danielle R, Orlow, Irene, Kanetsky, Peter A, Luo, Li, Busam, Klaus J, Sharma, Ajay, Kricker, Anne, Cust, Anne E, Anton-Culver, Hoda, Gruber, Stephen B, Gallagher, Richard P, Zanetti, Roberto, Rosso, Stefano, Sacchetto, Lidia, Dwyer, Terence, Gibbs, David C, Ollila, David W, Begg, Colin B, Berwick, Marianne, Thomas, Nancy E

“…Genome-wide association studies (GWAS) and candidate pathway studies have identified low-penetrant genetic variants associated with cutaneous melanoma. We…”
Get full text

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial by Giuliano, Armando E, Ballman, Karla V, McCall, Linda, Beitsch, Peter D, Brennan, Meghan B, Kelemen, Pond R, Ollila, David W, Hansen, Nora M, Whitworth, Pat W, Blumencranz, Peter W, Leitch, A. Marilyn, Saha, Sukamal, Hunt, Kelly K, Morrow, Monica

“…IMPORTANCE: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of…”
Get full text